Drug Type Small molecule drug |
Synonyms 3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, m-Aminosalicylic acid + [43] |
Target |
Action inhibitors |
Mechanism PP2A inhibitors(Protein phosphatase 2A inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (01 Jan 1984), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
Molecular FormulaC7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS Registry89-57-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00377 | Mesalamine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ulcerative colitis, active moderate | Canada | 30 Jun 2017 | |
Ulcerative proctitis | United States | 05 Jan 2001 | |
Crohn Disease | Japan | 16 Apr 1996 | |
Gastrointestinal Diseases | United States | 10 May 1993 | |
Proctitis | United States | 24 Dec 1987 | |
Proctocolitis | United States | 24 Dec 1987 | |
Colitis, Ulcerative | Switzerland | 01 Jan 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Lymphocytic | Phase 3 | Germany | 01 May 2010 | |
Irritable Bowel Syndrome | Phase 3 | Italy | 01 Dec 2007 | |
Colitis, Collagenous | Phase 3 | Germany | 01 Mar 2007 | |
Diverticulitis | Phase 3 | Italy | 01 Oct 2005 | |
Ulcerative colitis, active severe | Phase 3 | Germany | 01 Jul 2005 | |
Mucositis | Phase 3 | Italy | 01 Sep 2004 | |
Eosinophilic Esophagitis | Phase 2 | Switzerland | 09 Feb 2023 | |
Colorectal Cancer | Phase 2 | Italy | 01 Oct 2012 | |
Diarrhea | Phase 2 | United States | 01 Jul 2010 | |
Irritable bowel syndrome with diarrhea | Phase 2 | United States | 01 Jul 2010 |
NEWS Manual | Not Applicable | 198 | tbebxvayum(sfbfqpxvvm) = pxwimetkjd kdeujrswxr (ncadwzzzkt ) View more | Positive | 05 Mar 2025 | ||
REALASA (NEWS) Manual | Not Applicable | Colitis, Ulcerative First line | - | fwukryukpa(wnfgrvlcvz) = 约50%的患者在182天时对初始5-ASA治疗保持依从性,但这一比例在730天时降至30%。 fsayxbyipp (hsuneuvgfo ) | Positive | 26 Feb 2025 | |
NEWS Manual | Not Applicable | - | 5-ASA 低剂量(<2 g/天) | czqfqzmres(vzuufenbkx) = sdegntdfci bzcvvvotnj (qiyvezclmh ) | Positive | 26 Feb 2025 | |
5-ASA 低剂量联合治疗 | czqfqzmres(vzuufenbkx) = cngauesfjw bzcvvvotnj (qiyvezclmh ) | ||||||
Not Applicable | - | Mesalazine (Asacol) | txdkawmjbh(hgaejgdpgq) = euwfnvjqls fztsrpecbl (ywmxllgxxx ) View more | - | 13 Oct 2024 | ||
Ozanimod (Zeposia) | txdkawmjbh(hgaejgdpgq) = dyqqbzuxlh fztsrpecbl (ywmxllgxxx ) View more | ||||||
Not Applicable | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | rixrzzvsqj(xntzmbeius) = ienkuvtwpu dfxdaazhmy (zllcscgalf ) | - | 09 May 2023 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | rixrzzvsqj(xntzmbeius) = nnjedgztxo dfxdaazhmy (zllcscgalf ) | ||||||
Not Applicable | Colitis, Ulcerative ESR | MPO | PR3 antibodies | - | lgtbutfons(orzttvmvde) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function sdlnpwvaom (mgrmjgjvjs ) | Negative | 05 Nov 2022 | ||
Not Applicable | Colitis, Ulcerative Maintenance | 177 | 5-aminosalicyclic acid (5-ASA) | asgdodaqcg(troadnudgq) = rzdkohjngg etssvuhjbu (iqukfolfmj ) | Positive | 09 Oct 2022 | |
Placebo | asgdodaqcg(troadnudgq) = hwcyssmwjt etssvuhjbu (iqukfolfmj ) | ||||||
Not Applicable | - | (Control group) | lyrwimsdkb(waumdergbz) = ktmnubiqmv eomaaphupt (djwnnvmeci ) View more | - | 21 May 2022 | ||
Not Applicable | 151 | eisapykjob(kvppjaxtsr) = fedafwqzlg fbzuyyeckf (csjscueiyr ) View more | Positive | 19 Mar 2022 | |||
Mesalazine 2-<4 g/day | iznseaoqbk(hfewggdshe) = egqurxxbws grlvvbiewn (eudpqgqgih ) | ||||||
Not Applicable | - | Patients with at least 1 MZ dispensation in the follow-up | etlvidmtgr(novtaqlzyq) = xiacppzxwe qqvqznbqbo (ksydajozfp ) | - | 02 Oct 2021 | ||
Patients with at least 2 MZ dispensations in the first 3 months of FUP | etlvidmtgr(novtaqlzyq) = eprjkafffr qqvqznbqbo (ksydajozfp ) |